technology

press releases

Date Title and Summary Additional Formats
Toggle Summary Eptinezumab Selected as the International Nonproprietary Name for ALD403 View HTML
Toggle Summary BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of View HTML
Toggle Summary Company Finalizes ALD403 Pivotal Program Design and Confirms Planned Initiation of PROMISE 2 Phase 3 Study in 2016 Top-Line ALD403 PROMISE 1 Phase 3 Data Expected in First Half of 2017  BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its third quarter 2016 financial and operating results after the close of View HTML
Toggle Summary BOTHELL, Wash., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage company developing monoclonal antibody therapeutics, today announced the promotion of Larry Benedict to the position of Executive Vice President and Principal Accounting Officer. Mr. View HTML
Toggle Summary Alder Continues to Expand Leadership Team to Support the Advancement of ALD403 for Migraine Prevention View HTML
Toggle Summary BOTHELL, Wash., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of View HTML
Toggle Summary BOTHELL, Wash., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the View HTML
Toggle Summary Addition to Leadership Team Expands Commercialization Focus and Supports Continued Successful Advancement of ALD403 for Migraine Prevention View HTML
Toggle Summary BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of View HTML